Share on StockTwits

Shares of Smith & Nephew plc (NYSE:SNN) saw a significant decline in short interest in the month of July. As of July 31st, there was short interest totalling 394,959 shares, a decline of 38.5% from the July 15th total of 641,725 shares, Stock Ratings Network.com reports. Based on an average trading volume of 114,135 shares, the short-interest ratio is currently 3.5 days. Currently, 0.0% of the shares of the company are short sold.

SNN has been the subject of a number of recent research reports. Analysts at Morgan Stanley downgraded shares of Smith & Nephew plc from an “overweight” rating to an “equal weight” rating in a research note on Friday, August 15th. Separately, analysts at Panmure Gordon reiterated a “hold” rating on shares of Smith & Nephew plc in a research note on Monday, August 4th. Finally, analysts at Numis Securities Ltd reiterated a “hold” rating on shares of Smith & Nephew plc in a research note on Monday, August 4th. Nine research analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company. Smith & Nephew plc has a consensus rating of “Hold” and an average price target of $97.00.

Smith & Nephew plc (NYSE:SNN) opened at 86.85 on Wednesday. Smith & Nephew plc has a one year low of $57.99 and a one year high of $100.90. The stock has a 50-day moving average of $87.82 and a 200-day moving average of $82.01. The company has a market cap of $15.529 billion and a P/E ratio of 29.62.

Smith & Nephew plc (NYSE:SNN) last issued its quarterly earnings data on Friday, August 1st. The company reported $1.02 earnings per share for the quarter, beating the analysts’ consensus estimate of $0.94 by $0.08. On average, analysts predict that Smith & Nephew plc will post $4.21 earnings per share for the current fiscal year.

Smith & Nephew plc is a global medical devices business operating in the markets for orthopaedic reconstruction and trauma, endoscopy (NYSE:SNN) and advanced wound management.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.